Journal of International Psychiatry

Abstract: Objective To explore the effects of different doses of amisulpride combined with perospirone hydrochloride hydrate on glucose-lipid metabolism in patients with treatment-resistant schizophrenia (TRS). Methods A total of 60 TRS patients who were admitted to the hospital between June 2018 and June 2020 were enrolled as the research objects. They were divided into control group (normal-dose amisulpride combined with perospirone hydrochloride hydrate) and observation group (low-dose amisulpride combined with perospirone hydrochloride hydrate) by random number table, 30 cases in each group. The curative effect, scores of positive and negative syndrome scale (PANSS), glucose-lipid metabolism indexes and incidence of adverse reactions in both groups were recorded. Results After treatment, scores of negative, positive and general psychopathological symptoms, and total score of PANSS in both groups were significantly decreased. The scores of positive symptoms and total score of PANSS in observation group were significantly higher than those in control group (P<0.05). After treatment, levels of fasting blood glucose (FBG), fasting insulin (FINS), insulin resistance index (HOMA-IR), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in control group were significantly higher than those in observation group (P<0.05). There was no significant difference in total response rate between the two groups (P>0.05). The total incidence of adverse reactions in control group was significantly higher than that in observation group (26.67% vs 6.67%) (P<0.05). Conclusion The curative effect of perospirone hydrochloride hydrate combined with low-dose and normal-dose amisulpride is comparable on TRS. Low-dose amisulpride is beneficial to stabilize the level of glucose-lipid metabolism in TRS patients, with lower incidence of adverse reactions.

Key words: Schizophrenia; Amisulpride; Piperopilone; Glucose-lipid metabolism; Treatment-resistant